Key facts
- This page summarizes Emster Kurt von's Form 4 filing for Vera Therapeutics, Inc. (VERA).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 May 2021, 20:10.
Emster Kurt von - 17 May 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)
- Reporting relationship
- Director
- Issuer ticker
- VERA
- Reported as of
- 17 May 2021
- Net transaction value
- +$8,714,653
- SEC form
- 4
- Accepted by SEC
- 18 May 2021, 20:10:03 UTC
- Prior SEC filing
- 17 May 2021
- Next SEC filing
- 03 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph R. Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Emster Kurt von filed Form 4 for Vera Therapeutics, Inc. (VERA) on 18 May 2021.
Change
- Previous filing in this sequence was filed on 17 May 2021.
- Current net transaction value: +$8,714,653.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VERA
transaction
Class A Common Stock
Purchase
- Transaction value
- $214,656
- Shares
- +17,828
- Change %
- Price
- $12.04
- Shares after
- 17,828
- Date
- 17 May 2021
- Ownership
- Direct
- Footnotes
- F1
VERA
transaction
Class A Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,187,504
- Change %
- Price
- Shares after
- 2,187,504
- Date
- 18 May 2021
- Ownership
- See footnote
- Footnotes
- F2, F3, F4
VERA
transaction
Class A Common Stock
Purchase
- Transaction value
- $8,499,997
- Shares
- +772,727
- Change %
- +35%
- Price
- $11.00
- Shares after
- 2,960,231
- Date
- 18 May 2021
- Ownership
- See footnote
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VERA
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -2,187,504
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 May 2021
- Ownership
- See footnote
- Underlying class
- Class A Common Stock
- Underlying amount
- 2,187,504
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The price reported is a weighted-average price. The shares were purchased at prices ranging from $11.60 to $12.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Footnote F2
The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.
Footnote F3
The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8.
Footnote F4
From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.